Phase I and Pharmacokinetic Study of Biweekly PEP02 (Liposome Irinotecan) in Patients With Metastatic Colorectal Cancer Refractory to First-line Oxaliplatin-based Chemotherapy.
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics
- 04 Apr 2017 Status changed from active, no longer recruiting to completed.
- 01 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Mar 2012 Actual patient number (18) added as reported by ClinicalTrials.gov.